M. Nakamura

What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions

M. Moroi, Y. Enomoto, T. Kunimasa, 2022, Vaccines.

Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan

Y. Uyama, Y. Asahina, H. Yamada, 2014, Clinical pharmacology and therapeutics.

Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients.

J. Utsunomiya, Y. Toda, T. Yoshimura, 2021, Die Pharmazie.

Association between seasonal influenza vaccines and the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine Adverse Event Reporting System.

M. Fujimori, M. Nakamura, 2022, Die Pharmazie.

Impact of the COVID-19 pandemic on incidence and mortality of emergency cardiovascular diseases in Tokyo

Y. Maejima, T. Yoshikawa, H. Yoshino, 2023, Journal of Cardiology.